These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
362 related articles for article (PubMed ID: 25122609)
1. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. Venkata JK; An N; Stuart R; Costa LJ; Cai H; Coker W; Song JH; Gibbs K; Matson T; Garrett-Mayer E; Wan Z; Ogretmen B; Smith C; Kang Y Blood; 2014 Sep; 124(12):1915-25. PubMed ID: 25122609 [TBL] [Abstract][Full Text] [Related]
2. Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1. LeBlanc FR; Pearson JM; Tan SF; Cheon H; Xing JC; Dunton W; Feith DJ; Loughran TP Br J Haematol; 2020 Aug; 190(3):405-417. PubMed ID: 32124438 [TBL] [Abstract][Full Text] [Related]
3. Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression. Schrecengost RS; Keller SN; Schiewer MJ; Knudsen KE; Smith CD Mol Cancer Res; 2015 Dec; 13(12):1591-601. PubMed ID: 26271487 [TBL] [Abstract][Full Text] [Related]
4. Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Antoon JW; White MD; Slaughter EM; Driver JL; Khalili HS; Elliott S; Smith CD; Burow ME; Beckman BS Cancer Biol Ther; 2011 Apr; 11(7):678-89. PubMed ID: 21307639 [TBL] [Abstract][Full Text] [Related]
5. A novel sphingosine kinase inhibitor induces autophagy in tumor cells. Beljanski V; Knaak C; Smith CD J Pharmacol Exp Ther; 2010 May; 333(2):454-64. PubMed ID: 20179157 [TBL] [Abstract][Full Text] [Related]
6. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. French KJ; Zhuang Y; Maines LW; Gao P; Wang W; Beljanski V; Upson JJ; Green CL; Keller SN; Smith CD J Pharmacol Exp Ther; 2010 Apr; 333(1):129-39. PubMed ID: 20061445 [TBL] [Abstract][Full Text] [Related]
7. The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation. Sundaramoorthy P; Gasparetto C; Kang Y Cancer Med; 2018 Jul; 7(7):3257-3268. PubMed ID: 29761903 [TBL] [Abstract][Full Text] [Related]
8. The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells Zhang Y; Zhou L; Bandyopadhyay D; Sharma K; Allen AJ; Kmieciak M; Grant S Clin Cancer Res; 2019 Oct; 25(20):6195-6205. PubMed ID: 31358538 [TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Beljanski V; Lewis CS; Smith CD Cancer Biol Ther; 2011 Mar; 11(5):524-34. PubMed ID: 21258214 [TBL] [Abstract][Full Text] [Related]
11. Proteasomal degradation of sphingosine kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells. McNaughton M; Pitman M; Pitson SM; Pyne NJ; Pyne S Oncotarget; 2016 Mar; 7(13):16663-75. PubMed ID: 26934645 [TBL] [Abstract][Full Text] [Related]
12. Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640. Lewis CS; Voelkel-Johnson C; Smith CD Oncotarget; 2016 Sep; 7(37):60181-60192. PubMed ID: 27517489 [TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells. Ding X; Chaiteerakij R; Moser CD; Shaleh H; Boakye J; Chen G; Ndzengue A; Li Y; Zhou Y; Huang S; Sinicrope FA; Zou X; Thomas MB; Smith CD; Roberts LR Oncotarget; 2016 Apr; 7(15):20080-92. PubMed ID: 26956050 [TBL] [Abstract][Full Text] [Related]
14. Targeting ovarian cancer and chemoresistance through selective inhibition of sphingosine kinase-2 with ABC294640. White MD; Chan L; Antoon JW; Beckman BS Anticancer Res; 2013 Sep; 33(9):3573-9. PubMed ID: 24023282 [TBL] [Abstract][Full Text] [Related]
15. ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer. Yang J; Yang C; Zhang S; Mei Z; Shi M; Sun S; Shi L; Wang Z; Wang Y; Li Z; Xie C Cancer Biol Ther; 2015; 16(8):1194-204. PubMed ID: 26054751 [TBL] [Abstract][Full Text] [Related]
16. Sphingosine kinase 2 inhibitor ABC294640 suppresses neuronal excitability and inhibits multiple endogenously and exogenously expressed voltage-gated ion channels in cultured cells. Zhang F; Hu W; Qu L; Cang C Channels (Austin); 2020 Dec; 14(1):216-230. PubMed ID: 32615066 [TBL] [Abstract][Full Text] [Related]
17. Sphingosine kinase-2 Inhibitor ABC294640 Enhances Doxorubicin-Induced Apoptosis of NSCLC Cells via Altering Survivin Expression. Hasanifard L; Samadi N; Rashtchizadeh N; Dastmalchi S; Karimi P Drug Res (Stuttg); 2018 Jan; 68(1):45-53. PubMed ID: 28950390 [TBL] [Abstract][Full Text] [Related]
18. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623 [TBL] [Abstract][Full Text] [Related]
19. The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo. Venant H; Rahmaniyan M; Jones EE; Lu P; Lilly MB; Garrett-Mayer E; Drake RR; Kraveka JM; Smith CD; Voelkel-Johnson C Mol Cancer Ther; 2015 Dec; 14(12):2744-52. PubMed ID: 26494858 [TBL] [Abstract][Full Text] [Related]
20. Targeting sphingosine kinase 2 by ABC294640 inhibits human skin squamous cell carcinoma cell growth. Zhou J; Chen J; Yu H Biochem Biophys Res Commun; 2018 Mar; 497(2):535-542. PubMed ID: 29428730 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]